Abstract

Lipid metabolism and glucose homeostasis are two intertwined metabolic processes that are often dysregulated 
in conditions such as obesity, insulin resistance, and type 2 diabetes (T2D). Given the complexity of these 
disorders, therapeutic strategies targeting both lipid and glucose metabolism are critical for effective 
management. Lipid-based nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), and 
nanostructured lipid carriers (NLCs), offer promising platforms for the dual modulation of lipid metabolism and 
glucose homeostasis. These nanocarriers can encapsulate bioactive compounds that regulate lipid and glucose 
pathways, provide targeted delivery to specific tissues, and enhance the bioavailability and therapeutic effects of 
drugs. This review explores the role of lipid-based nanocarriers in the dual modulation of lipid metabolism and 
glucose homeostasis, highlighting their mechanisms of action, therapeutic applications, and the challenges 
associated with their development and clinical translation.